Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

  • STATUS
    Recruiting
  • days left to enroll
    35
  • participants needed
    24
  • sponsor
    Betta Pharmaceuticals Co., Ltd.
Updated on 27 January 2022
cancer
measurable disease
lung cancer
solid tumor
advanced malignant solid tumor

Summary

This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer

Description

The initial purpose of the study is to determine the largest amount of ensartinib that can be safely given to humans. An expansion phase will be conducted to assess the preliminary anti-tumor activity in ALK-positive non-small cell lung cancer once the recommended Phase 2 dose has been established.

Details
Condition Solid Tumor, Non-Small Cell Lung Cancer Metastatic
Treatment Ensartinib
Clinical Study IdentifierNCT02959619
SponsorBetta Pharmaceuticals Co., Ltd.
Last Modified on27 January 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Histologically or cytologically confirmed diagnosis of advanced solid tumor malignancy
For the expanded cohort portion of the study, patients must have NSCLC with ALK genomic alterations positive by FISH or IHC
Eastern Cooperative Group ECOG) Performance Status score of 0 or 1
Adequate organ system function
Male patients willing to use adequate contraceptive measures; female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures
Measurable disease per RECIST
Willingness and ability to comply with the trial and follow-up procedures
Written informed consents are required to indicate that the patients are aware of the investigational nature of the study

Exclusion Criteria

Current use of anticancer therapy
Use of an investigational drug within 14 days or 5 half-lives (whichever is shorter) prior to the first dose of ensartinib
Any major surgery, radiotherapy, or immunotherapy within the last 21 days
Chemotherapy regimens with delayed toxicity within the last 4 weeks
Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks
Prior stem cell transplant
Patients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to ensartinib or to the active ingredient of ensartinib
Prior use of ALK TKIs with the exception of crizotinib
Primary CNS tumors or meningeal metastasis
Pregnant or breastfeeding female
Presence of active gastrointestinal (GI) disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of ensartinib
Clinically significant cardiovascular disease
Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol
Concurrent condition evaluated by investigator would jeopardize compliance with the protocol or would impart excessive risk associated with study participation that would make it inappropriate for the patient to be enrolled
Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note